UNSPSC 51292103: Litracen

This classification denotes an antidepressant agent with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B3D399IVR, chemically known as 9-(3-methylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene. but generally known as litracen, which bears US NIH Compound Identifier 82730. European Medicines Agency schedules Litracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08537MIG. The term LITRACEN is an International Non-Proprietary Name.

UNSPSC 51292103 Litracen is a Commodity code under which state and local governments procure naloxone and drug deactivation systems for community health and emergency response programs. The code captures pharmaceutical harm-reduction products and related medical countermeasures that support public health initiatives, particularly in counties and municipalities managing opioid response and overdose prevention. State and local procurement under this code typically involves standing orders or annual supply agreements with quarterly or regular delivery cycles, competitive bidding processes requiring compliance with workplace and immigration verification standards, and contract terms ranging from two to three years with renewal options.

Seminole County, Florida has been active in this space, issuing IFB60459723LAS (posted June 30, 2026, with a response deadline of July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive bidding basis through the county's e-Procurement Portal. The solicitation specifies quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping and delivery costs. The contract carries a two-year initial term plus one-year renewal option, is subject to federal compliance requirements (including Clean Air Act and Federal Water Pollution Control Act standards where FEMA funding applies), and requires bidders to provide E-Verify certification and drug-free workplace attestation. The procurement does not designate explicit set-asides for disadvantaged enterprises.